Abstract
GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer
Journal of clinical oncology, Vol.41(4_suppl), pp.TPS766-TPS766
02/01/2023
DOI: 10.1200/jco.2023.41.4_suppl.tps766
Abstract
TPS4184 Background: While treatment of pancreatic cancer has advanced, survival rates remain low. Stereotactic body radiotherapy (SBRT; high dose per fraction radiation) may exhibit improved clinical outcomes in locally advanced pancreatic cancer but carries potential gastrointestinal toxicity risks (Zhong 2017). Rucosopasem (GC4711) is one of a class of investigational selective dismutase mimetics that rapidly and specifically converts superoxide to hydrogen peroxide (Riley 2006). Studies have shown that normal cells tolerate hydrogen peroxide fluxes better than cancer cells (Doskey 2016). As radiation response modifiers, dismutase mimetics have the potential to increase tumor control of SBRT without compromising radiation safety (El-Mahdy 2020, Sishc 2021). In a pilot phase 1/2 trial in patients with pancreatic cancer, avasopasem, a dismutase mimetic related to rucosopasem, nearly doubled median overall survival in patients receiving SBRT vs placebo plus SBRT. Improvements versus placebo were also observed in local tumor control, time to metastases, and progression-free survival. Altogether, these data support the hypothesis that rucosopasem may improve survival and the benefit-risk ratio of SBRT by improving efficacy without increasing gastrointestinal toxicity. Materials/Methods: GRECO-2 is a phase 2, multicenter, randomized, double-blind, placebo-controlled study (NCT04698915) to determine the effect of adding rucosopasem to SBRT on overall survival in patients with borderline resectable or locally advanced, unresectable nonmetastatic pancreatic cancer following initial chemotherapy with a FOLFIRINOX-based regimen or a gemcitabine doublet. Approximately 160 patients will be randomized (approximately 35 sites) to receive rucosopasem 100 mg or placebo via IV infusion over 15 minutes, prior to each SBRT fraction (5 x 10 Gy). Patients judged to be resectable will undergo surgical exploration within 8 weeks after SBRT. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, locoregional control, time to metastasis, surgical resection rate, RO resection rate, best overall response, in-field local response, and safety (acute and late toxicities). Exploratory endpoints include PRO-CTCAE and CA19-9 normalization. This trial is now enrolling. Clinical trial information: NCT04698915.
Details
- Title: Subtitle
- GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer
- Creators
- Todd Anthony Aguilera - The University of Texas Southwestern Medical CenterParag Parikh - Henry Ford HospitalMaged Ghaly - Northwell HealthSarah E. Hoffe - Moffitt Cancer CenterJoseph M. Herman - Northwell HealthJoseph Michael Caster - University of IowaDae Won Kim - Moffitt Cancer CenterJames Costello - Moffitt Cancer CenterMokenge Peter Malafa - Moffitt Cancer CenterMuhammad S. Beg - The University of Texas Southwestern Medical CenterElizabeth Charlotte MoserEugene Paul KennedyKara TerryMichael Kurman
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.41(4_suppl), pp.TPS766-TPS766
- Publisher
- American Society of Clinical Oncology (ASCO)
- DOI
- 10.1200/jco.2023.41.4_suppl.tps766
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: Galera Therapeutics, Inc
- Language
- English
- Date published
- 02/01/2023
- Academic Unit
- Radiation Oncology
- Record Identifier
- 9984530384302771
Metrics
1 Record Views